Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Tirzepatide monotherapy demonstrates 2022% average body weight reduction in clinical trials, with robust appetite suppression through dual GIP/GLP-1 activation
Long-Term Safety Evidence While many peptide therapies have been evaluated only in short-term trials, AOD-9604 benefits from long-term safety data extending to 24 weeks of continuous administration
Gray-market peptides can create risks beyond the peptide itself, raising concerns over product quality, purity, and inconsistent formulation
Start from the weekly milligram dose, then convert it to milliliters and U-100 syringe units using the vial concentration
US$ 26.04
US$ 22.04
US$ 24.81
US$ 21.79
US$ 27.72
US$ 25.35
US$ 20.46
US$ 25.24
US$ 20.90
US$ 22.06
